Evidence map›Paper›PMID 21876447›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2011

Changing predictors of mortality over time from cART start: implications for care.

Christopher J Hoffmann, Katherine L Fielding, Victoria Johnston, Salome Charalambous, Craig Innes, Richard D Moore, Richard E Chaisson, Alison D Grant, Gavin J Churchyard

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christopher J HoffmannDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. choffmann@jhmi.edu
Katherine L Fielding
Victoria Johnston
Salome Charalambous
Craig Innes
Richard D Moore
Richard E Chaisson
Alison D Grant
Gavin J Churchyard

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICER01DA011602 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 1998 to 2013
$10.8M
UNDERLYING MECHANISMS OF SCHISTOSOME/SNAIL COMPATIBILITYR01AI016137 · NIAID · OREGON STATE UNIVERSITY · PI BAYNE, CHRISTOPHER JEFFREY · 1989 to 2012
$3.1M
DOT-HAART for HIV-Infected South African AdultsR01AI055359 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHAISSON, RICHARD E. · 2003 to 2008
$2.6M
MID CAREER INVESTIGATOR AWARDK24DA000432 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2000 to 2009
$1.5M
Alcohol and HIV Treatment and Clinical ProgressionR01AA016893 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2008 to 2011
$1.3M
CAUSES OF AND ASSOCIATIONS WITH DEATH DURING LONG TERM HAART IN AFRICAK23AI083099 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HOFFMANN, CHRISTOPHER J · 2010 to 2014
$671k
Alcohol and HIV Progression in the Hopkins HIV CohortR21AA015032 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2004 to 2005
$388k
Underlying mechanisms of schistosome/snail compatibilityR21AI016137 · NIAID · OREGON STATE UNIVERSITY · PI BAYNE, CHRISTOPHER JEFFREY · 2001 to 2001
$273k
SCHISTOSOME-SNAIL COMPATIBILITY: UNDERLYING MECHANISMSR22AI016137 · NIAID · OREGON STATE UNIVERSITY · PI BAYNE, CHRISTOPHER JEFFREY · 1985 to 1991
–
Department of HealthMedical Research Council G0700837NIAAA NIH HHS AA16893NIAAA NIH HHS R01 AA016893NIAAA NIH HHS R21 AA015032NIAID NIH HHS AI016137NIAID NIH HHS AI083099NIAID NIH HHS AI5535901NIAID NIH HHS K23 AI083099NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI016137NIAID NIH HHS R21 AI016137NIAID NIH HHS U01 AI069918NIDA NIH HHS DA00432NIDA NIH HHS DA11602NIDA NIH HHS K24 DA000432NIDA NIH HHS R01 DA011602NIDA NIH HHS U01 DA036935Wellcome Trust
6 · The paper itself

Abstract

objectiveTo determine predictors of mortality and changes in those predictors over time on combination antiretroviral therapy (cART) in South Africa.

designA cohort study.

methodsUsing routine clinic data with up to 4 years follow-up after antiretroviral therapy initiation and with death ascertainment from a national vital statistics register, we used proportional hazards modeling to assess baseline and time-updated predictors of mortality and changes in strength of those predictors over time on cART. Furthermore, we compared CD4 count among individuals who died by duration on cART.

resultsFifteen thousand sixty subjects (64% men, median CD4 count 127 cells/mm³) started antiretroviral therapy between January 2003 and January 2008. Over a median follow-up of 1.8 years, 2658 subjects died. The baseline characteristics of WHO stage, hemoglobin, CD4 count, HIV RNA level, and symptoms were all associated with mortality during the first 12 months of cART but lost association thereafter. However, time-updated factors of CD4 count, body mass index, symptoms, anemia, and HIV RNA suppression remained strong predictors of death. Most recent CD4 count before death rose from 71 during the first 3 months of cART to 175 cells per cubic millimeter after >3 years of cART.

conclusionOver 4 years of cART, risk of death declined and associations with mortality changed. An increase in CD4 count at death and changing associations with mortality may suggest a shift in causes of death, possibly from opportunistic infections to other infections and chronic illnesses.

Indexed as

Antiretroviral Therapy, Highly ActiveAdultAnti-HIV AgentsCohort StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedModels, StatisticalPredictive Value of TestsPrognosisSouth AfricaTime FactorsAnti-HIV Agents

Identifiers

PMID21876447
PMCPMC4009722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.